2LCK

Structure of the mitochondrial uncoupling protein 2 determined by NMR molecular fragment replacement

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N TROSY-HSQC	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
2	3D TROSY-HNCA	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
3	3D TROSY-HN(CO)CA	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
4	3D TROSY-HNCACB	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
5	3D TROSY-HN(CO)CACB	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
6	3D TROSY-HN(CA)CO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
7	3D TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
8	3D (HN,HN)-HMQC-NOESY-TROSY	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
9	3D J(NH)-scaled TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
10	3D J(NH)-scaled TROSY-HNCO	0.5 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride, 2 w/v DNA nanotube	95% H2O/5% D2O	150	6.5	ambient	33
11	3D quantitative J(C'Ca) TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
12	3D quantitative J(C'Ca) TROSY-HNCO	0.5 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride, 2 w/v DNA nanotube	95% H2O/5% D2O	150	6.5	ambient	33
13	3D quantitative J(C'N) TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
14	3D quantitative J(C'N) TROSY-HNCO	0.5 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride, 2 w/v DNA nanotube	95% H2O/5% D2O	150	6.5	ambient	33
15	3D TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2-SL1, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
16	3D TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2-SL2, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
17	3D TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2-SL3, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33
18	3D TROSY-HNCO	0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] UCP2-SL4, 5 mM guanosine diphosphate, 150 mM dodecylphosphocholine, 1 mM cardiolipin, 2 mM dimyristoyl-phosphatidylcholine, 5 mM beta-mercatpoethanol, 30 mM potassium phosphate, 80 mM sodium chloride	95% H2O/5% D2O	150	6.5	ambient	33

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	600

NMR Refinement
Method	Details	Software
RDC-based Molecular Fragment Replacement, simulated annealing	determining local structural segments by RDC-based MFR protocol, determining the spatial arrangement of the MFR-derived segments using PRE distance restraints	NMRPipe

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	30
Conformers Submitted Total Number	15
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	processing	NMRPipe	3.0	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
2	data analysis	NMRDraw	3.0	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	chemical shift assignment	XEASY		Bartels et al.
4	structure solution	X-PLOR NIH	2.26	Schwieters, Kuszewski, Tjandra and Clore
5	refinement	X-PLOR NIH	2.26	Schwieters, Kuszewski, Tjandra and Clore
6	refinement	In_house_python_script

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.